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Increased morbidity and fetal growth restriction are reported in uninfected children born to human immunodeficiency virus type 
1 (HIV-1)–infected women treated with antiretroviral (ARV) therapy. Viruses and/or pharmacological interventions such as ARVs 
can induce metabolic stress, skewing the cell’s immune response and restricting (cell) growth. Novel metabolomic techniques pro-
vided the opportunity to investigate the impact of fetal HIV-1 and combination ARV therapy (cART) exposure on the infants’ 
immune metabolome. Peroxidized lipids, generated by reactive oxygen species, were increased in cART/HIV-1–exposed infants, 
indicating altered mitochondrial functioning. The lipid metabolism was further dysregulated with increased triglyceride species and 
a subsequent decrease in phospholipids in cART/HIV-1–exposed infants compared to control infants. Proinflammatory immune 
mediators, lysophospholipids as well as cytokines such as CXCL10 and CCL3, were increased whereas anti-inflammatory metab-
olites from the cytochrome P450 pathway were reduced in cART/HIV-1–exposed infants. Taken together, these data demonstrate 
that the fetal metabolism is impacted by maternal factors (cART and HIV-1) and skews physiological immune responses toward 
inflammation in the newborn infant.
Keywords. immune metabolism; fetal development; HIV-1; metabolomics; antiretroviral therapy.
 
Although the global rollout of antiretroviral (ARV) treatment 
to prevent mother-to-child transmission of human immunode-
ficiency virus type 1 (HIV-1) has dramatically improved sur-
vival of the 1.4 million infants born annually to HIV-1–infected 
women [1], increased morbidity is still reported [2, 3]. Studies 
have shown in utero growth restriction, altered cardiac func-
tioning, and enhanced susceptibility to infections in children 
born to HIV-1–infected women [2, 4–6]. Furthermore, there 
are concerns regarding neurological abnormalities in combi-
nation ARV therapy (cART)/HIV-1–exposed infants [7, 8]. In 
addition, immune responses from both the innate as well as 
the adaptive arm of the immune system are altered in cART/
HIV-1–exposed infants [9–11]. The underlying mechanisms 
responsible for these clinical and immunological observations 
remain largely unknown, in particular as even infants born to 
immune-competent women receiving cART with an undetect-
able viral load still present with immune alterations [10].
During infections but also through pharmacological inter-
ventions, metabolic stress impacts the cell’s immune response. 
Changes in nutrient levels are sensed by nutrient-sensing (stress) 
receptors in the endoplasmic reticulum (ER) [12], which activate 
the unfolded-protein response [12] and subsequent nuclear fac-
tor kappa-light-chain-enhancer of activated B cells (NF-kB) and 
the c-Jun N-terminal kinase (JNK) pathways [13]. Furthermore, 
reactive oxygen species (ROS) generated upon mitochondrial 
stress are potent inducers of the inflammasome and interleukin 
(IL) 1B production [14]. Pregnancy is a condition of extreme 
nutrient consumption and places stringent demands on the 
maternal and fetal metabolism [15]. When nutrient levels are 
impaired, for example, in children with restricted in utero 
growth, proinflammatory cytokines in placenta are increased 
[16, 17], suggesting an immune-metabolic link.
Furthermore, ARVs such as zidovudine, which is frequently 
used in prevention of mother-to-child transmission (PMTCT) 
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HIV-1 regimens, reduce the DNA polymerase in mitochondria 
and can lead to mitochondrial stress [18]. In cART/HIV-1–
exposed infants, altered levels of mitochondrial DNA as well 
as acyl-carnitine profiles have been detected, indicating that 
mitochondrial functioning may be impaired in these infants 
[8, 19–23]. We hypothesized that metabolic homeostasis is dis-
rupted in infants exposed in utero to maternal HIV-1 infection 
and cART, which results in proinflammatory fetal immune 
responses. Using novel metabolomic techniques, we detected 
extensive lipid and mitochondrial dysregulation in cord blood–
derived plasma of cART/HIV-1–exposed infants compared 
with HIV-1–unexposed control infants, which was associated 
with a differential increase of proinflammatory cytokines. These 
results reveal potential mechanisms by which metabolic pro-
cesses can shape the fetal immune system, providing the under-
lying conditions for proinflammatory responses.
METHODS
Patients
Plasma was obtained from cord blood collected from 12 infants 
born to HIV-1–infected women and from 15 control infants 
born to HIV-1–negative mothers (and not exposed to cART). 
The required sample size was informed by previously published 
work in patas monkeys as well as in cART/HIV-1–exposed 
infants [24, 25]. The samples were collected at the Academic 
Medical Center (Amsterdam, the Netherlands). The study was 
approved by the local ethics committee and informed con-
sent was obtained from participating mothers. For the cART/
HIV-1–exposed group, maternal viral load, CD4+ T-cell count, 
total triglyceride and total cholesterol levels, and antiretroviral 
medications were obtained from the patient hospital records 
(Supplementary Table  1). Total triglyceride and total choles-
terol levels were not available for the control group. The cART 
regimen that was used for each patient (Supplementary Table 1) 
was based on viral resistance or the patient’s treatment regimen 
prior to conception. Per European guidelines, the cART regi-
men consisted of 2 nucleoside reverse transcriptase inhibitors 
(NRTIs; primarily zidovudine and lamivudine) and either a 
protease inhibitor (PI; ritonavir-boosted lopinavir or nelfina-
vir) or a nonnucleoside reverse transcriptase inhibitor (NNRTI; 
nevirapine) [26]. Five of the 12 women were receiving cART 
treatment prior to pregnancy. One patient took tenofovir during 
the first trimester of pregnancy combined with lamivudine and 
nevirapine, while another received nevirapine (NNRTI), in 
combination with ritonavir-boosted lopinavir and saquinavir 
due to her resistance profile. During birth, all HIV-1–infected 
mothers were given intrapartum zidovudine. The clinical profile 
at delivery of the 12 mothers in the study indicates that the virus 
was suppressed appropriately, consistent with a mother-to-child 
transmission rate of <1%. HIV-1 infection was evaluated at 
birth, 5 weeks, and 3 months by measuring RNA viral load with 
polymerase chain reaction and confirmed at 18 months of age, 
by showing absence of detectable HIV immunoglobulin G. All 
infants were confirmed to be HIV-1–negative.
Sample Collection
Plasma was separated by centrifugation at 5000g for 10 minutes 
at 4°C and stored at –20°C prior to analysis and transported to 
the Biomedical Facility Leiden (Leiden University) for metabo-
lomics analysis.
Quality Control Samples
Quality control (QC) samples were used during the metab-
olomics analyses. Equal volumes of each study sample were 
pooled to generate a QC pool. A set of QC samples was then 
included in the analyses with the experimental groups on the 
individual metabolomics platforms, and the QC samples were 
distributed randomly through the samples prior to liquid chro-
matography–mass spectrometry (LC-MS) analysis. In addition, 
independent duplicate samples were randomly selected. Only 
those metabolites for which the duplicate and QC samples had 
a relative standard deviation <30% were considered to be mea-
sured accurately.
LC-MS Targeted Metabolomics Analyses
Targeted metabolomics analyses were performed using standard 
operating procedures based on previously published methods 
[27, 28]. The detailed procedures and target lists are provided in 
the Supplementary Data (Experimental Procedures).
Positive and Negative Lipid Profiling
Ten-microliter and 20-μL serum samples were spiked with 
calibration and internal standards and extracted using isopro-
pyl alcohol (for the positive lipid platforms) or methanol (for 
the negative lipid platforms). Samples were analyzed using an 
ACQUITY ultra performance liquid chromotography system 
coupled to a 6530 Accurate Mass Quadrupole time-of-flight 
(Agilent Technologies, Santa Clara, California) [28].
Oxylipin Profiling
One hundred fifty–microliter serum samples were spiked 
with calibration and internal standards and diluted with a 5% 
methanol solution containing 0.1% acetic acid. Samples were 
extracted using solid-phase extraction (HLB Oasis, Waters 
Chromatography) and analyzed using an high performance liq-
uid chromotography system coupled to a 6460 Agilent Triple 
Quadrupole mass spectrometer (Agilent Technologies) [27].
Soluble Immunological Factors
A multiparameter Luminex bead assay (Invitrogen) was used 
to measure the levels of the following soluble factors in 25 µL 
of plasma in accordance with the manufacturer’s instructions: 
IL-1Β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17A, IL-18, inter-
feron (IFN)–α, IFN-γ, CXCL10, tumor necrosis factor, CCL3, 
CCL4, CCL5, TNF-related apoptosis-inducing ligand (TRAIL), 
and colony stimulating factor 2 (CSF2). Human serum 
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C-reactive protein was measured with enzyme-linked immu-
nosorbent assay (R&D Systems, Abingdon, United Kingdom).
Statistical Analyses
A combination of univariate bioinformatics approaches was per-
formed using the R script‒based online tool Metaboanalyst 3.0 [29]. 
Mann–Whitney U test and Fisher exact test were used to compare 
differences in patient demographics on continuous and categori-
cal variables, respectively, using SPSS version 23.0 software (IBM 
Corp, Armonk, New York). Pearson correlation coefficients were 
calculated using SPSS. Significant Pearson correlations between 
immunological markers and metabolites were visualized using the 
Metscape application within Cytoscape (version 3.2.1) [30].
Following LC-MS analysis, peak integration, and deter-
mination of the relative ratios between metabolites and their 
corresponding internal standards, QC quality assurance was 
performed. First, we evaluated for outlier samples based on a 
95% confidence region in a Hotelling T-squared distribution 
test. No outlier samples were identified in all the platforms 
measured. Significant metabolites were identified based on 
the following 2 criteria: (1) a fold change (FC) ≥1.25 or ≤0.75, 
indicating a 25% increase or decrease, respectively, and (2) a 
P value <.05 using the Mann–Whitney U test. The significant 
univariate results are shown on a volcano plot as colored sym-
bols. Pearson correlation coefficients were generated using 
log-transformed normalized data in SPSS. During the correla-
tion analyses, each metabolite was tested against 8 immunolog-
ical markers, and no multiple testing correction was performed, 
as only class responses—and not individual correlations—were 
interpreted. Significant correlations were defined as a Pearson 
coefficient (r) > 0.46 or r < –0.46 and P < .05.
RESULTS
In this study, 12 cART-treated HIV-1–infected and 15 HIV-1–
negative pregnant women were included. The baseline maternal 
group demographics (Table 1) were similar, except ethnicity. In 
HIV-1–infected women, triglyceride (1.8  mmol/L) and total 
cholesterol (5 mmol/L) levels were within upper-normal ranges 
for pregnant women [31] and none of the HIV-1–infected 
women or in the control group had diabetes or were diagnosed 
with gestational diabetes. The HIV-1–infected women had a 
CD4+ T-cell count in the first trimester exceeding 200  ×  106 
cells/L in all women (Table 1). The CD4+ T-cell counts further 







P ValueMedian (75% CI) Median (75% CI)
Age, y 32.6 (30.7–33.2) 28.5 (28.2–32.4) .50a
Prepregnancy weight, kg 64.5b (62.7–66.9) 68.5 (65.7–74.2) .41a
Prepregnancy BMI 22.04b (22.3–24.1) 23.67 (22.6–26.1) .79a
Total triglyceridesc, mmol/L … 1.80d (1.5–2.1)
Total cholesterolc, mmol/L … 5d (4.6–5.4)
Glucosec, mmol/L … 4.30d (4.2–4.7)
Ethnicity (white/black/South Asian), No. 9/4/2 3/9/0 .03e
Gestational diabetes (yes/no), No. 0/15 0/12
Viral load, copies/mL Trimester 1 … 528.5 (1269–9084)
Trimester 2 … 50 (47.81–281)
Trimester 3f … <50
CD4 count, × 106 cells/L Trimester 1 … 455 (465.5–594.5)
Trimester 2 … 520 (511.4–650.6)





Gestation period, wk 40 (37.63–39.97) 39.25 (38.74–39.82) .57a
Birth weight, g 3380 (3128–3494) 3085 (3009–3472) .34a
Apgar score (5 min) 10 (9.5–9.9) 10 (9.1–9.9) .44a
Mode of delivery (vaginal/cesarean),  
No.
14/1 8/4 .14e
Gender (male/female), No. 8/7 7/5 .55e
Abbreviations: BMI, body mass index; CI, confidence interval.
aMann–Whitney U test.
bOne mising value.
cMeasured at the end of the second trimester.
dTwo missing values.
eFisher exact test.
fAll mothers were below the limit of detection.
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delivery, viral loads were undetectable in all women (Table 1). 
Five of the 12 women were receiving cART treatment prior to 
pregnancy. None of the HIV-1–infected mothers transmitted 
the virus to their infant. The cART/HIV-1–exposed and con-
trol infants had a similar distribution with regards to gestational 
age, birth weight, Apgar scores, mode of delivery, and sex.
Oxidative Stress in cART/HIV-1–Exposed Infants
Reactive oxygen species are produced upon mitochondrial dys-
function, in particularly upon cell stress. Therefore, to assess 
the outcome of mitochondrial dysfunctioning, we measured 
ROS-catalyzed lipid peroxidation metabolites [32]. Predefined 
criteria identified 13 significantly increased ROS-produced 
oxylipins with a 0.25 FC and P < .05 (see Statistical Analyses). 
Moreover, none of the peroxidized oxylipins were decreased in 
the cART/HIV-1–exposed infants (Figure 1 and Supplementary 
Table 2). These findings point toward mitochondrial dysfunc-
tioning in cART/HIV-1–exposed infants, resulting in increased 
ROS production. ROS are strong activators of lipogenesis, and 
we therefore next investigated the infants’ lipid profiles.
Lipid Profiles in cART/HIV-1–Exposed Infants Are Characterized by 
Hypertriglyceridemia and Decreased Phospholipid Species
We evaluated the effect of in utero cART/HIV-1 exposure on 
lipid metabolism in infants by measuring their triglyceride, 
diacylglycerol, sphingomyelin, phospholipid, cholesteryl ester, 
and free fatty acid cord blood profiles. Free fatty acids are the 
simplest lipid metabolites, with the phospholipids contain-
ing 2 free fatty acids bound to a glycerol phosphate backbone. 
Phospholipids are critical building blocks in cell and organelle 
membrane structure, function and integrity, with their metab-
olism regulated by the different phospholipases. Similarly, 
the diacylglycerol (triglyceride precursors) and triglycerides 
metabolites are important in free fatty acid storage acting as an 
energy reservoir, and have a lesser role in membrane structure 
and signaling (diacylglycerols). The sphingomyelins are mem-
bers of the unique sphingolipids and play an important role in 
the central nervous system, as well as in lipid rafts (together 
with cholesterol). In total, 2 diacylglycerols and 32 triglycerides 
were increased. In particularly, triglycerides with long and very 
long acyl chains were significantly increased in cART/HIV-1–
exposed infants. As only free fatty acids are transported across 
the placenta to the fetus [33], and no differences in free fatty 
acids between cART/HIV-1–exposed infants and control infants 
were detected, these increased triglyceride levels in the infant 
depend on nonspecific fatty acid elongation and endogenous 
triglyceride biosynthesis. Although not yet described in cART/
HIV-1–exposed infants, hypertriglyceridemia is commonly 
observed in HIV-1–infected adults, in particular, in patients 
treated with ritonavir-boosted lopinavir, to which 8 of 12 infants 
were exposed [34]. Triglyceride synthesis occurs primarily 
in the endoplasmic reticulum (ER). To remove the surplus of 
triglycerides from the ER, the ER commences the formation 
of lipid droplets with an outer rim of ER membrane‒derived 
phospholipids. We therefore evaluated phosphatidylcholines 
and phosphatidylethanolamines, which are the most prevalent 
glycerophospholipids and components of the ER membrane. 
Three phosphatidylcholines, 2 plasmalogen phosphatidylcho-
lines, and 1 phosphatidylethanolamine metabolite were signifi-
cantly decreased in cART/HIV-1–exposed infants compared 
to control infants (Figure 2 and Supplementary Table 2). 
Depletion of ER membrane-derived phospholipids upon 
hypertriglyceridemia is an important ER stressor. In addition, 
phospholipids—and specifically unsaturated lysophospholip-
ids—have anti-inflammatory properties, inhibiting NF-κB acti-
vation via the mitogen-activated protein kinase pathway [35], 
whereas saturated lysophospholipids have a proinflammatory 
effect. We subsequently assessed the lysophospholipids in both 
cART- and HIV-exposed infants and controls. Of note, no dif-
ferences were detected in the cholesteryl ester profiles, whereas 
2 sphingomyelin species were decreased in the cART/HIV-1–
exposed infants compared to the controls.
Increased Saturated and Decreased Unsaturated Lysophospholipids in 
cART/HIV-1–Exposed Infants
Lysophospholipids are derived from the phospholipases-medi-


























Figure 1. Volcano plot of the reactive oxygen species–produced oxylipin profiles 
of combination antiretroviral therapy (cART)/human immunodeficiency virus type 1 
(HIV-1)–exposed infants vs control infants. Thirteen metabolites were identified as 
significantly increased (black rings) in the cART/HIV-1–exposed-infants compared 
to control infants. Volcano plots visualizes the log10 (Mann–Whitney P value) on the 
y-axis and the log2 (fold change [FC]) on the x-axis for each metabolite compared 
between the cART/HIV-1–exposed infants vs control infants. The dotted lines rep-
resent the significance thresholds with FC > 1.25 and FC < 0.75 on the x-axis and P < 
.05 on the y-axis. Abbreviations: 8-iso-PGF2α, 8-iso-prostaglandin F2α; cART, com-
bination antiretroviral therapy; FC, fold change; HDoHE, hydroxyl-docosahexaenoic 
acid; HEPE, hydroxy-eicosapentaenoic acid; HETE, hydroxy-eicosatetraenoic acid; 
HIV, human immunodeficiency virus.
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in the phospholipids, resulting in a lysophospholipid (fatty acid 
bound to the phospho-glycerol backbone) and a free fatty acid. 
Lysophospholipids released into the circulation, function as 
immune modulators and fatty acid transporters. Two saturated 
stearic acid isomers (SN1-lysophosphatidylcholine C18:0 and 
SN2-lysophosphatidylcholine C18:0) and 2 saturated lysophos-
phatidylethanolamine species (C16:0 and C18:0) were signifi-
cantly increased in cART/HIV-1–exposed infants compared 
to control infants (Figure  3A and Supplementary Table  2). 
The unsaturated ω-9 SN1-lysophosphatidylcholine C20:3 was 
reduced in cART/HIV-1–exposed infants compared to control 
infants. The ratios of saturated vs unsaturated lysophosphati-
dylcholines and lysophosphatidylethanolamines were signifi-
cantly (P < .01) increased in the cART/HIV-1–exposed infants 
compared to the control infants due to increased saturated 
lysophospholipids species (Figure  3B). In contrast, this ratio 
was balanced in the control group, indicating that unexposed 
infants maintain homeostatic control.
Anti-Inflammatory Oxylipin Mediators Are Decreased in cART/HIV-1–
Exposed Infants
Like lysophospholipids, the oxylipins are enzymatically syn-
thesized from the free fatty acids produced by enzyme-me-
diated hydrolysis of membrane phospholipids in 3 major 
pathways. First, free fatty acids can follow the cyclooxygen-
ase-II (COX) pathway, leading to well-known prostaglandins 
or thromboxanes [36]. COX pathway metabolites are critical 
in inflammatory responses during infection and are common 
targets for therapeutic interventions [36]. Free fatty acids can be 
also oxidized by cytochrome P450 (CYP450) enzymes resulting 
in the epoxy-fatty acid oxylipins, which play a predominantly 
anti-inflammatory role [37]. Last, the third oxidation pathway 
is the 5-,12- and 15-lipoxygenase (LOX) pathway. Important 
downstream metabolites of the LOX pathway are hydroxy-fatty 
acids and leukotrienes, which play a role in inflammation, for 
example in asthma [36]. The CYP450 oxylipins 5,6-dihydroxye-
icosatrienoic acid (DiHETre), 8,9-DiHETre, and 11,12-DiHETre 
were significantly reduced in the cART/HIV-1–exposed infants, 
indicating impaired CYP450 metabolism in this group (Figure 4 
and Supplementary Table 2). Interestingly, 11,12-epoxyeico-
satrienoic acid, which was significantly reduced in cART/
HIV-1–exposed infants compared to control infants, is a potent 
inhibitor of the NF-κB pathway [38]. Epoxyeicosatrienoic acids 
also activate PPARα, which in turn induces mitochondrial 
β-oxidation as well as regulates the secretion of insulin and 
glucagon, thereby acting as antihyperlipidemia and antihyper-
glycemia agents [39]. The reduction in DiHETrE levels there-
fore indicates a reduced antihyperlipidemia capacity in cART/
HIV-1–exposed infants.
The other 4 identified enzyme-derived oxylipin metabolites 
are in the LOX pathway and included 20-carboxy-leukotriene 
B4, protectin DX (PDX), 5-hydroxyeicosapentaenoic acid 
(5-HEPE), and 9-hydroxyoctadecatrienoic acid (9-HOTrE). 
Notably, 20-carboxy-leukotriene B4, which was increased in 
cART/HIV-1–exposed infants, is the stable downstream metab-
olite of leukotriene B4, a potent proinflammatory mediator 
in asthma. Overall, the changes in oxylipin levels measured 
in cART/HIV-1–exposed infants indicate a skewing toward 
metabolites with proinflammatory capacity while compensa-
tory mechanisms are reduced.
Dyslipidemia and Peroxidized Lipids Indicating Mitochondrial 
Dysfunction Are Associated With Increased Proinflammatory Cytokines 
and Chemokines in cART/HIV-1–Exposed Infants
To determine associations between the proinflammatory lipid 
mediators, cytokines, and chemokines were measured [10]. The 
levels of IL-4, IL-5, IL-13, IL-17A, IL-18, and IFN-α and IFN-γ 
were below the detection limit, and CRP was >3 log lower than 
the clinically relevant cutoff (data not shown). Correlations 
between the metabolites and immune markers were calculated. 
Figure 5 shows networks for the metabolite classes that correlated 
significantly to the immunological markers (Supplementary 
Tables 3–7). ROS-catalyzed lipid peroxidation products cor-
related strongly with CXCL10 and to a lesser extent to CCL4 
(Figure  5A). Triglycerides, diacylglycerols, and phospholipids 
(Figure 5B) correlated with IL-8, CCL3, and, to a lesser extent, 
CCL4 and IL-1Β. Furthermore, saturated and unsaturated lys-




















Figure 2. Volcano plot of lipid profiles of combination antiretroviral therapy 
(cART)/ human immunodeficiency virus type 1 (HIV-1)–exposed infants vs control 
infants. Overall, 32 triglycerides (black rings) and 2 diacylglycerols (gray rings) were 
increased with 6 phospholipids (large dark grey circles) having decreased levels in 
cART/HIV-1–exposed infants compared to control infants. Sphingomyelins (black 
dots) and phospholipids (small dark grey dot) with P < .05 are also shown. Volcano 
plots visualizes the log10 (Mann–Whitney P value) on the y-axis and the log2 (fold 
change [FC]) on the x-axis for each metabolite compared between the cART/HIV-1–
exposed infants vs control infants. The dotted lines represent the significance 
thresholds with FC > 1.25 and FC < 0.75 on the x-axis and P < .05 on the y-axis.
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negatively associated with CCL3, CCL4, and CXCL10. Products 
from the LOX and COX pathways were positively associated 
with IL-1Β, IL-8, CCL3, CCL4, and CXCL10 (Figure  5D). 
Together, these studies show an accumulation of proinflamma-
tory metabolite mediators such as saturated lysophospholipids, 
triglycerides, and lipid peroxidation metabolites, which were 
associated with proinflammatory cytokines and chemokines.
DISCUSSION
Using comprehensive and highly sensitive metabolomics tools, 
we demonstrate that the metabolome in infants exposed to 
long-term cART in utero is characterized by cell stress and dys-
regulation of metabolites with immune modulatory capacities 
in cART/HIV-1–exposed infants. These studies further suggest 
that physiologic metabolic functioning during fetal develop-
ment is critical for maintaining a tolerant immune milieu. When 
metabolic homeostasis is disrupted and cell stress is induced 
either by viruses or pharmacological interventions, the tolerant 
fetal immune system can be skewed toward proinflammatory 
immune responses, with potential consequences for pregnancy 
outcome and postnatal immune competence.
The augmented peroxidized lipids provide a robust indica-
tion of the in vivo consequences of altered mitochondrial func-
tioning in cART/HIV-1–exposed infants. As these children are 
not infected with HIV-1 and zidovudine is actively transported 
across the placenta [40], the altered mitochondrial functioning 
in cART/HIV-1–exposed infants is likely due to the effects of 
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Figure 3. The lysophospholipid profiles of combination antiretroviral therapy (cART)/ human immunodeficiency virus type 1 (HIV-1)–exposed infants vs control infants. A, 
Lysophospholipid profiles: The increased saturated lysophospholipids and decreased unsaturated lysophospholipid in the plasma of cART/HIV-1–exposed infants are shown 
as dark grey rings on the volcano plot. Volcano plots visualizes the log10 (Mann–Whitney P value) on the y-axis and the log2 (fold change [FC]) on the x-axis for each metabolite 
compared between the cART/HIV-1–exposed infants vs control infants. The dotted lines represent the significance thresholds with FC &gt; 1.25 and FC &lt; 0.75 on the x-axis 
and P < .05 on the y-axis. B, Lysophospholipid saturation composition average: a significant change in the ratio of saturated vs unsaturated C18 lysophosphatidylethanolamine 
and lysophosphatidylcholine species was found in the cART/HIV-1–exposed infants compared to control infants. Ratios revealed an almost doubling in the percentage of 
stearic acid vs oleic and linoleic acid species in cART/HIV-1–exposed infants. Black, gray, and light gray represents the group-averaged stearic acid (C18:0), oleic acid (C18:1), 
and linoleic acid (C18:2), respectively. Unpaired t test on the intergroup ratios. **P &lt; .01. Abbreviations: cART, combination antiretroviral therapy; FA, fatty acid; FC, fold 
change; HIV, human immunodeficiency virus; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; SFA, saturated fatty acid; SN, stereospecific numbering; UFA, 
unsaturated fatty acid.
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electron transport chain’s complexes assembling. Interestingly, 
the 1 infant without in utero NRTI exposure had a lipid per-
oxidation metabolite profile comparable to those of the control 
infants. None of the infants presented with lipodystrophy; how-
ever, exposure time was also shorter than when lipodystrophy 
is generally clinically visible in cART-treated patients. The con-
sequences of mitochondrial toxicity may persist after exposure 
has ceased as studies in patas monkeys showed abnormal car-
diac mitochondrial morphology at 1 year and aneuploidy per-
sisting for up to 3 years of age [41, 42]. Furthermore, a recent 
study by Jao et  al showed that the acyl-carnitine profile and 
branched amino acids were associated with an altered insulin 
metabolism in cART/HIV-1–exposed infants at 6 weeks of age 
[43]. Together, these observations underscore the need for stud-
ies assessing whether changes in the fetal metabolism resulting 
from exposure to ARV have long-term clinical consequences. 
Furthermore, ARVs with reduced toxicity compared to zidovu-
dine are available and used in the setting of treatment of HIV-1–
infected adults and children as well as PMTCT. The avoidance 
of zidovudine in PMTCT regimens is now a realistic option to 
prevent zidovudine-associated metabolic dysregulation.
Significant changes were further detected in the lipid metab-
olism in cART/HIV-1–exposed infants. Birth is a metabolic 
stressful period for both mother and infant, with little recent 
food intake. Therefore, significant changes of metabolites 
reflect metabolic functioning and less likely of differences in 
food intake between HIV-1–infected mothers and controls. 
Increased triglycerides are a well-known phenomenon in 
HIV-1–infected patients and have been attributed to several 
causes, including increased type 1 interferons, microbial trans-
location, and several antiretroviral drugs [34, 44]. Of these, 
PIs are most notorious in inducing hypertriglyceridemia. The 
reduced levels of CYP4A and CYP2B6 eicosanoids in cART/
HIV-1–exposed infants support a direct effect of PIs on fetal 
cells, as PIs have been shown to inhibit CYP450 enzyme activity 
[45]. After cessation of PI treatment, adults’ triglyceride levels 
return to normal values, suggesting that this may also occur 
in the cART/HIV-1–exposed infants. However, consequences 
of the altered lipid metabolism may reach beyond its effect on 
immune responses. Of note, the increased triglyceride levels in 
cART/HIV-1–exposed infants may be an underestimate of the 
impact of in utero HIV-1 and cART exposure, as triglyceride 
levels in black populations are lower compared to white popula-
tions, and more cART/HIV-1–exposed infants were black com-
pared to the control infants [46]. These findings suggest that 
lopinavir/ritonavir-based regimes might not be the ideal candi-
date for PMTCT of HIV-1 [47], even as monotherapy. However, 
darunavir, which has potent antiviral capacity in combination 
with a more favorable lipid profile, might be a more suitable 
candidate in cART and is currently also evaluated in the setting 
of PMTCT as monotherapy [48] (ClinicalTrials.gov identifier 
NCT02738502). Furthermore, integrase inhibitors may present 
a less toxic alternative as well for PMTCT.
Our study at the interface of immune and metabolic 
responses provides new insights in the role of metabolites 
with immunomodulatory capacities prior to birth. Lipid per-
oxidation products positively correlated with CXCL10, which 
is an interferon-stimulated gene. West et  al described that in 
mice with mitochondrial stress, interferon-stimulated genes 
were upregulated [49]. Additionally, hypertriglyceridemia 
can activate the ER stress’s unfolded protein response and 
downstream proinflammatory pathways. Last, significantly 
lower levels of the potent anti-inflammatory arachidonic 
acid‒derived CYP450 metabolites were detected in the cART/
HIV-1–exposed infants, reducing compensatory homeostatic 
mechanisms in these infants. Further studies are required to 
understand how these changes in metabolites and associated 
immune responses indicating low-level inflammation provide 
the underlying conditions for the described morbidity such as 
increased susceptibility to infections of cART/HIV-1–exposed 
infants [2, 3, 21]. Although enhanced immune activation may 
seem at odds with increased susceptibility to infections, the 
continuous low-level immune activation in, for example, obese 
patients has been proposed to contribute to enhanced sus-





























Figure 4. Volcano plot of cyclooxygenase, lipoxygenase, and cytochrome P450 
oxylipin profiles of combination antiretroviral therapy (cART)/human immuno-
deficiency virus type 1 (HIV-1)–exposed infants vs control infants. Significantly 
increased or decreased oxylipins in the cART/HIV-1–exposed-infants compared 
to the control infants are shown as grey rings. Volcano plots visualizes the log10 
(Mann–Whitney P value) on the y-axis and the log2 (fold change [FC]) on the 
x-axis for each metabolite compared between the cART/HIV-1–exposed infants 
vs control infants. The dotted lines represent the significance thresholds with 
FC > 1.25 and FC < 0.75 on the x-axis and P < .05 on the y-axis. Abbreviations: 
20-carboxy-LTB4, 20-carboxy-leukotriene B4; cART, combination antiretroviral ther-
apy; DiHDoHE, dihydroxydocosa-4,7,11,13,15,19-hexaenoic acid; DiHETrE, dihy-
droxy-eicosatrienoic acid; EpDPE, epoxy-docosapentaenoic acid; FC, fold change; 
HEPE, hydroxy-eicosapentaenoic acid; HIV, human immunodeficiency virus; HOTrE, 
hydroxy-9Z,11E,15Z-octadecatrienoic acid.
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Phospholipid & lysophospholipid classes
Triglyceride, diacylglycerol, sphingomyelin,
cholesteryl esters & free fatty acid classes
Enzymatic oxylipin classes
Figure 5. Pearson correlation networks illustrating the correlation between metabolite classes and classic immunological markers. The correlation network shows the 
correlations (P < .05) between the measured cytokines and chemokines and the normalized metabolites for reactive oxygen species lipid peroxidation metabolites (A); tri-
glycerides, sphingomyelins, diacylglycerols, cholesteryl esters, and free fatty acids (B); phospholipids and lysophospholipids (C); and enzymatic oxylipins (D) (Supplementary 
Tables 3–7). Abbreviations: 5-iPGF2α-VI, 5-isoprostane F2α VI; 8-iso-PGF2α, 8-iso-prostaglandin F2α; CE, cholesteryl ester; Cer, ceramides; COX, cyclooxygenase; CYP450, 
cytochrome P450; DG, diacylglycerol; DiHDoHE, dihydroxydocosahexaenoic acid; DiHETE, dihydroxyeicosatetraenoic acid; DiHETrE, dihydroxyeicosatrienoic acid; DiHODE, 
dihydroxyoctadecadienoic acid; DiHOME, dihydroxyoctadecenoic acid; EpDPE, epoxydocosapentaenoic acid; EpETrE, epoxy-eicosatrienoic acid; FA, free fatty acids; HDoHE, 
hydroxy-docosahexaenoic acid; HETE, hydroxyeicosatetraenoic acid; HETrE, hydroxyeicosatrienoic acid; HEPE, hydroxyeicosapentaenoic acid; HHTrE, hydroxyheptadecatrie-
noic acid; HODE, hydroxyoctadecadienoic acid; HOTrE, hydroxy-9Z,11E,15Z-octadecatrienoic acid; KETE, oxo-eicosatetraenoic acid; KODE, oxo-octadecadienoic acid; LPC, 
lysophosphatidylcholine; LPC(O), plasmalogen lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; LOX, lipoxygenase; LT, leukotrine; PC, phosphatidylcholine; PC(O), 
plasmalogen phosphatidylcholine; PE, phosphatidylethanolamine; PE(O), plasmalogen phosphatidylethanolamine; PG, prostaglandin; SM – sphingomyelins; SN, stereospe-
cific position; TG, triglyceride; Trail, TNF-related apoptosis-inducing ligand; TriHOME, trihydroxy-octadecenoic acid; TX, thromboxane.
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cART/HIV-1–exposed infants partially resembles this pheno-
type and could contribute to the clinical observations.
Next to avoidance of more toxic regimens, interventions 
including antioxidants and carnitines could be explored to 
restore homeostasis and ameliorate immunometabolic dys-
regulation in HIV-1–infected women and their infants in set-
tings where alternatives are not available. Furthermore, when 
investigating alternative PMTCT regimens, highly sensitive 
novel omics approaches such as metabolomics techniques used 
here, but also transcriptomics or epigenetic analyses, provide 
a unique opportunity to identify biomarkers in the context of 
prenatal exposure to ARVs and HIV-1. These techniques would 
provide a powerful tool to complement pharmacokinetics 
studies in clinical trials. Studies investigating adverse effects 
of prenatal exposure of ARVs can be further strengthened by 
investigating paired prenatal maternal samples and longitudinal 
infant samples.
In conclusion, our results demonstrate dysregulation of sev-
eral metabolic pathways in infants with in utero exposure to 
cART and HIV-1, providing the underlying conditions for a 
proinflammatory milieu observed in these infants. These data 
represent a novel framework in which metabolic dysregulation 
in the fetus is critical in shaping the earliest human immune 
responses, with potential consequences for fetal development 
and immunocompetence in the infant.
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